11 Facts About Talimogene laherparepvec

Talimogene laherparepvec, sold under the brand name Imlygic, is a biopharmaceutical medication used to treat melanoma that cannot be operated on; it is injected directly into a subset of lesions which generates a systemic immune response against the recipient's cancer.

Talimogene laherparepvec is a genetically engineered herpes virus .

Talimogene laherparepvec is delivered by injecting it directly into tumors, thereby creating a systemic anti-tumor immune response.

Talimogene laherparepvec has been shown to extend survival in patients with Stage IIIb-IVM1a melanoma and patients who have not received prior systemic therapy for melanoma.

Talimogene laherparepvec is taken up by normal cells and cancer cells like the wild type herpes simplex virus, it is cleared in the same way.

Related searches

Talimogene laherparepvec directly destroys the cancer cells it infects, inducing a systemic immune response against the patient's cancer.

Talimogene laherparepvec is a biopharmaceutical drug; it is an oncolytic herpes virus that was created by genetically engineering a strain of herpes simplex virus 1 taken from a person infected with the virus, rather than a laboratory strain.

Talimogene laherparepvec is the world's first approved oncolytic immunotherapy, i e it was designed to provide systemic anti-tumor effects through the induction of an anti-tumor immune response.

Talimogene laherparepvec was created and initially developed by BioVex, Inc under the brand OncoVEX.

Talimogene laherparepvec was approved by the U S Food and Drug Administration to treat melanoma in October 2015.

Amgen estimated that talimogene laherparepvec would be priced at per patient at the time it was approved.